Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer's study, with a new target in their sights
With the evidence increasingly weighing in against amyloid beta as the best solo target for Alzheimer’s, a startup out of San Francisco has identified a brand new target and now has a $76 million B round to put it through its first proof-of-concept study.
The scientific inspiration for the biotech comes from UCSF psychiatrist Steve Dominy, who identified a bacterial pathogen that he believes plays a key role in the pathology of the disease. Initially working out of JLABS Bay Area facility, Cortexyme has now completed animal studies as well as a Phase I safety test to set the stage for a Phase II human study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
